$Faraday Future Intelligent Electric Inc.(FFIE.US$ 🚀🚀 Exchange shares 🚀🚀 $Allarity Therapeutics(ALLR.US$
Translated
1
$CureVac(CVAC.US$
"A research result shows that rats fed with raw milk infected with avian influenza virus have a large amount of virus present in their lungs. The research report indicates that there is a risk for humans consuming such beverages."
"A research result shows that rats fed with raw milk infected with avian influenza virus have a large amount of virus present in their lungs. The research report indicates that there is a risk for humans consuming such beverages."
3
$Virgin Galactic(SPCE.US$
ORANGE COUNTY, Calif.--(MAY 1, 2024) -- Virgin Galactic Holdings, Inc. (NYSE: SPCE) today announced the ‘Galactic 07’ flight window will open Saturday, June 8, 2024. This will be the Company’s second spaceflight this year and 12th to date.
Virgin Galactic’s spaceship will again be converted into a suborbital science lab, with VSS Unity carrying an Axiom Space affiliated researcher astronaut who will conduct multiple human-tend...
ORANGE COUNTY, Calif.--(MAY 1, 2024) -- Virgin Galactic Holdings, Inc. (NYSE: SPCE) today announced the ‘Galactic 07’ flight window will open Saturday, June 8, 2024. This will be the Company’s second spaceflight this year and 12th to date.
Virgin Galactic’s spaceship will again be converted into a suborbital science lab, with VSS Unity carrying an Axiom Space affiliated researcher astronaut who will conduct multiple human-tend...
3
$CureVac(CVAC.US$
CureVac N.V. has scheduled its annual general meeting (AGM) for June 24, 2024, in Amsterdam, to discuss the 2023 annual report, adopt annual accounts, and address management and supervisory board matters, including appointments and liability releases. Shareholders must register by June 21 to attend in person or via webcast, with no voting or questions allowed during the webcast. The company does not foresee paying dividends, prefer...
CureVac N.V. has scheduled its annual general meeting (AGM) for June 24, 2024, in Amsterdam, to discuss the 2023 annual report, adopt annual accounts, and address management and supervisory board matters, including appointments and liability releases. Shareholders must register by June 21 to attend in person or via webcast, with no voting or questions allowed during the webcast. The company does not foresee paying dividends, prefer...
1
$CureVac(CVAC.US$
As of 2024, CureVac's COVID-19 vaccine is undergoing clinical trials. Currently, the second-generation mRNA COVID-19 vaccine developed in collaboration with GSK is in Phase II trials.
Progress and Trial Data
In the Phase II clinical trials, CureVac's monovalent vaccine CV0601 and bivalent vaccine CV0701 both showed positive results. The monovalent vaccine, targeting the Omicron BA.4-5 variant, demonstrated a fi...
As of 2024, CureVac's COVID-19 vaccine is undergoing clinical trials. Currently, the second-generation mRNA COVID-19 vaccine developed in collaboration with GSK is in Phase II trials.
Progress and Trial Data
In the Phase II clinical trials, CureVac's monovalent vaccine CV0601 and bivalent vaccine CV0701 both showed positive results. The monovalent vaccine, targeting the Omicron BA.4-5 variant, demonstrated a fi...
1
4
Translated
1
$CureVac(CVAC.US$ CureVac's sales for the first quarter of 2024 were €124 million, exceeding expectations of €12.03 billion
Translated
3
3
$CureVac(CVAC.US$
$Novavax(NVAX.US$
As empathy spread, vaccine stocks became the focus of investors' attention. Among the many vaccine stocks, I think the two stocks with the highest returns are CureVac and NovaVax, respectively. Both companies' stock prices reached three digits during the peak of empathy, showing strong market performance and investment potential.
First place: CureVac
$CureVac(CVAC.US$
CureVac is a German biotechnology company focused on the development and commercialization of mRNA vaccines. Its innovative mRNA technology has been widely recognized and applied around the world. At the peak of empathy, CureVac's stock price broke through three digits, showing its huge market potential and investment value. Given its continued investment in R&D and the expansion of the global market, I believe CureVac has great potential for future growth.
Second place: Novavax
$Novavax(NVAX.US$
Novavax is an American biotech company focused on developing innovative vaccines. Its vaccine technology based on recombinant proteins has been used significantly during the COVID-19 pandemic. Novavax's vaccine has been approved and promoted in many countries and regions around the world, making its stock price resentful...
$Novavax(NVAX.US$
As empathy spread, vaccine stocks became the focus of investors' attention. Among the many vaccine stocks, I think the two stocks with the highest returns are CureVac and NovaVax, respectively. Both companies' stock prices reached three digits during the peak of empathy, showing strong market performance and investment potential.
First place: CureVac
$CureVac(CVAC.US$
CureVac is a German biotechnology company focused on the development and commercialization of mRNA vaccines. Its innovative mRNA technology has been widely recognized and applied around the world. At the peak of empathy, CureVac's stock price broke through three digits, showing its huge market potential and investment value. Given its continued investment in R&D and the expansion of the global market, I believe CureVac has great potential for future growth.
Second place: Novavax
$Novavax(NVAX.US$
Novavax is an American biotech company focused on developing innovative vaccines. Its vaccine technology based on recombinant proteins has been used significantly during the COVID-19 pandemic. Novavax's vaccine has been approved and promoted in many countries and regions around the world, making its stock price resentful...
Translated
5
1